Gland Pharma Ltd Q1 net profits up 11.8% at Rs350.65cr as higher input costs offset sales growth

Gland Pharma Ltd reported 30.5% rise in total revenues for the Jun-21 quarter on consolidated basis at Rs1,153.90cr

Jul 22, 2021 11:07 IST India Infoline News Service

Gland Pharma Ltd reported 30.5% rise in total revenues for the Jun-21 quarter on consolidated basis at Rs1,153.90cr  as pharma demand in India and abroad remained buoyant on a yoy and on a sequential basis. On a sequential basis also, the revenues were up 29.98% compared to Rs887.75cr revenues in the Mar-21 quarter.

During the first quarter, Gland Pharma had 17 product SKUs including 12 new molecules launched. As of Jun-21, Gland has 286 ANDA filings in the US of which 239 are approved and 47 are pending.

The net profit for the Jun-21 quarter was up 11.82% at Rs350.65cr. However, the profit growth was much higher sequentially at 34.65%. One of the principal reasons for the profit growth being lower than the sales growth is the sharp spike in cost of materials, power/fuel costs and employee benefit charges.

Net margins at 30.39% in Jun-21 quarter were lower than 35.47% in the Jun-20 quarter but better than 29.33% NPM in the sequential Mar-21 quarter. In the last 1 year, in line with global trend, input cost spike has been a challenge.


Financial highlights for Jun-21 compared yoy and sequentially


Gland Pharma
Rs in Crore Jun-21 Jun-20 YOY Mar-21 QOQ
Total Income (Rs cr) ₹ 1,153.90 ₹ 884.21 30.50% ₹ 887.75 29.98%
Net Profit (Rs cr) ₹ 350.65 ₹ 313.59 11.82% ₹ 260.41 34.65%
Diluted EPS (Rs) ₹ 21.37 ₹ 20.24 ₹ 15.88
Net Margins 30.39% 35.47% 29.33%

Related Story

Open Free Demat Account (Rs699)